Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2009

01-02-2009 | Original Paper

RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors

Authors: He-Yu Zhang, Long Jin, Gail A. Stilling, Katharina H. Ruebel, Kendra Coonse, Yoshinori Tanizaki, Avraham Raz, Ricardo V. Lloyd

Published in: Endocrine | Issue 1/2009

Login to get access

Abstract

Galectin-3 is expressed in a cell-type specific manner in human pituitary tumors and may have a role in pituitary tumor development. In this study, we hypothesized that Galectin-3 is regulated by RUNX proteins in pituitary tumors. Transcription factor prediction programs revealed several putative binding sites in the LGALS3 (Galectin-3 gene) promoter region. A human pituitary cell line HP75 was used as a model to study LGALS3 and RUNX interactions using Chromatin immunoprecipitation assay and electrophoresis mobility shift assay. Two binding sites for RUNX1 and one binding site for RUNX2 were identified in the LGALS3 promoter region. LGALS3 promoter was further cloned into a luciferase reporter, and the experiments showed that both RUNX1 and RUNX2 upregulated LGALS3. Knock-down of either RUNX1 or RUNX2 by siRNA resulted in a significant downregulation of Galectin-3 expression and decreased cell proliferation in the HP 75 cell line. Immunohistochemistry showed a close correlation between Galectin-3 expression and RUNX1/RUNX2 level in pituitary tumors. These results demonstrate a novel binding target for RUNX1 and RUNX2 proteins and suggest that Galectin-3 is regulated by RUNX1 and RUNX2 in human pituitary tumor cells by direct binding to the promoter region of LGALS3 and thus may contribute to pituitary tumor progression.
Literature
1.
M.P. Shekhar, P. Nangia-Makker, L. Tait, F. Miller, A. Raz, Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am. J. Pathol. 165, 1931–1941 (2004)PubMed
2.
H.C. Gong, Y. Honjo, P. Nangia-Makker, V. Hogan, N. Mazurak, R.S. Bresalier, A. Raz, The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 59, 6239–6245 (1999)PubMed
3.
F.T. Liu, G.A. Rabinovich, Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29–41 (2005)CrossRefPubMed
4.
K. Yamaoka, K. Mishima, Y. Nagashima, A. Asai, Y. Sanai, T. Kirino, Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J. Neurosci. Res. 59, 722–730 (2000)CrossRefPubMed
5.
Y. Takenaka, H. Inohara, T. Yoshii, K. Oshima, S. Nakahara, S. Akahani, Y. Honjo, Y. Yamamoto, A. Raz, T. Kubo, Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 195, 111–119 (2003)CrossRefPubMed
6.
R.C. Hughes, The galectin family of mammalian carbohydrate-binding molecules. Biochem. Soc. Trans. 25, 1194–1198 (1997)PubMed
7.
R.C. Hughes, Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim. Biophys. Acta 1473, 172–185 (1999)PubMed
8.
D. Riss, L. Jin, X. Qian, J. Bayliss, B.W. Scheithauer, W.F. Young Jr., S. Vidal, K. Kovacs, A. Raz, R.V. Lloyd, Differential expression of galectin-3 in pituitary tumors. Cancer Res. 63, 2251–2255 (2003)PubMed
9.
K.H. Ruebel, L. Jin, X. Qian, B.W. Scheithauer, K. Kovacs, N. Nakamura, H. Zhang, A. Raz, R.V. Lloyd, Effects of DNA methylation on galectin-3 expression in pituitary tumors. Cancer Res. 65, 1136–1140 (2005)CrossRefPubMed
10.
M. Stock, H. Schafer, S. Stricker, G. Gross, S. Mundlos, F. Otto, Expression of galectin-3 in skeletal tissues is controlled by Runx2. J. Biol. Chem. 278, 17360–17367 (2003)CrossRefPubMed
11.
A. Costessi, A. Pines, P. D’Andrea, M. Romanello, G. Damante, L. Cesaratto, F. Quadrifoglio, L. Moro, G. Tell, Extracellular nucleotides activate Runx2 in the osteoblast-like HOBIT cell line: a possible molecular link between mechanical stress and osteoblasts’ response. Bone 36, 418–432 (2005)CrossRefPubMed
12.
L. Jin, E. Kulig, X. Qian, B.W. Scheithauer, N.L. Eberhardt, R.V. Lloyd, A human pituitary adenoma cell line proliferates and maintains some differentiated functions following expression of SV40 large T antigen. Endocr. Pathol. 9, 169–184 (1998)CrossRef
13.
K. Cartharius, K. Frech, K. Grote, B. Klocke, M. Haltmeier, A. Klingenhoff, M. Frisch, M. Bayerlein, T. Werner, MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21, 2933–2942 (2005)CrossRefPubMed
14.
T. Tsunoda, T. Takagi, Estimating transcription factor bindability on DNA. Bioinformatics 15, 622–630 (1999)CrossRefPubMed
15.
D. Levanon, V. Negreanu, Y. Bernstein, I. Bar-Am, L. Avivi, Y. Groner, AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 23, 425–432 (1994)CrossRefPubMed
16.
Y. Kamachi, E. Ogawa, M. Asano, S. Ishida, Y. Murakami, M. Satake, Y. Ito, K. Shigesada, Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J. Virol. 64, 4808–4819 (1990)PubMed
17.
I.N. Melnikova, B.E. Crute, S. Wang, N.A. Speck, Sequence specificity of the core-binding factor. J. Virol. 67, 2408–2411 (1993)PubMed
18.
A.L. Zaiman, A.F. Lewis, B.E. Crute, N.A. Speck, J. Lenz, Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores. J. Virol. 69, 2898–2906 (1995)PubMed
19.
G. Huang, K. Shigesada, K. Ito, H.J. Wee, T. Yokomizo, Y. Ito, Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 20, 723–733 (2001)CrossRefPubMed
20.
Y.W. Zhang, N. Yasui, K. Ito, G. Huang, M. Fujii, J. Hanai, H. Nogami, T. Ochi, K. Miyazono, Y. Ito, A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc. Natl. Acad. Sci. USA 97, 10549–10554 (2000)CrossRefPubMed
21.
J. Kononen, L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, S. Leighton, J. Torhorst, M.J. Mihatsch, G. Sauter, O.P. Kallioniemi, Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844–847 (1998)CrossRefPubMed
22.
H. Miyoshi, M. Ohira, K. Shimizu, K. Mitani, H. Hirai, T. Imai, K. Yokoyama, E. Soeda, M. Ohki, Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res. 23, 2762–2769 (1995)CrossRefPubMed
23.
M.M. Kadrofske, K.P. Openo, J.L. Wang, The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch. Biochem. Biophys. 349, 7–20 (1998)CrossRefPubMed
24.
Y. Yamaguchi, M. Kurokawa, Y. Imai, K. Izutsu, T. Asai, M. Ichikawa, G. Yamamoto, E. Nitta, T. Yamagata, K. Sasaki, K. Mitani, S. Ogawa, S. Chiba, H. Hirai, AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J. Biol. Chem. 279, 15630–15638 (2004)CrossRefPubMed
25.
Y.W. Zhang, S.C. Bae, G. Huang, Y.X. Fu, J. Lu, M.Y. Ahn, Y. Kanno, T. Kanno, Y. Ito, A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol. Cell. Biol. 17, 4133–4145 (1997)PubMed
26.
T.K. Howcroft, J.D. Weissman, A. Gegonne, D.S. Singer, A T lymphocyte-specific transcription complex containing RUNX1 activates MHC class I expression. J. Immunol. 174, 2106–2115 (2005)PubMed
27.
T. Fukumori, N. Oka, Y. Takenaka, P. Nangia-Makker, E. Elsamman, T. Kasai, M. Shono, H.O. Kanayama, J. Ellerhorst, R. Lotan, A. Raz, Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res. 66, 3114–3119 (2006)CrossRefPubMed
28.
N. Oka, S. Nakahara, Y. Takenaka, T. Fukumori, V. Hogan, H.O. Kanayama, T. Yanagawa, A. Raz, Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res. 65, 7546–7553 (2005)PubMed
29.
M. Volante, F. Bozzalla-Cassione, F. Orlandi, M. Papotti, Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch. 444, 309–312 (2004)CrossRefPubMed
30.
F. Roncaroli, B.W. Scheithauer, G. Cenacchi, E. Horvath, K. Kovacs, R.V. Lloyd, P. Abell-Aleff, M. Santi, A.J. Yates, ‘Spindle cell oncocytoma’ of the adenohypophysis: a tumor of folliculostellate cells? Am. J. Surg. Pathol. 26, 1048–1055 (2002)CrossRefPubMed
31.
P. Ducy, T. Schinke, G. Karsenty, The osteoblast: a sophisticated fibroblast under central surveillance. Science 289, 1501–1504 (2000)CrossRefPubMed
32.
B.E. Crute, A.F. Lewis, Z. Wu, J.H. Bushweller, N.A. Speck, Biochemical and biophysical properties of the core-binding factor alpha2 (AML1) DNA-binding domain. J. Biol. Chem. 271, 26251–26260 (1996)CrossRefPubMed
33.
T. Kanno, Y. Kanno, L.F. Chen, E. Ogawa, W.Y. Kim, Y. Ito, Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol. Cell. Biol. 18, 2444–2454 (1998)PubMed
34.
H. Kagoshima, K. Shigesada, M. Satake, Y. Ito, H. Miyoshi, M. Ohki, M. Pepling, P. Gergen, The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet. 9, 338–341 (1993)CrossRefPubMed
35.
Q. Wang, T. Stacy, M. Binder, M. Marin-Padilla, A.H. Sharpe, N.A. Speck, Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA 93, 3444–3449 (1996)CrossRefPubMed
36.
T. Okuda, J. van Deursen, S.W. Hiebert, G. Grosveld, J.R. Downing, AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321–330 (1996)CrossRefPubMed
37.
T. Komori, H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R.T. Bronson, Y.H. Gao, M. Inada, M. Sato, R. Okamoto, Y. Kitamura, S. Yoshiki, T. Kishimoto, Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755–764 (1997)CrossRefPubMed
38.
F. Otto, A.P. Thornell, T. Crompton, A. Denzel, K.C. Gilmour, I.R. Rosewell, G.W. Stamp, R.S. Beddington, S. Mundlos, B.R. Olsen, P.B. Selby, M.J. Owen, Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89, 765–771 (1997)CrossRefPubMed
39.
D. Levanon, D. Bettoun, C. Harris-Cerruti, E. Woolf, V. Negreanu, R. Eilam, Y. Bernstein, D. Goldenberg, C. Xiao, M. Fliegauf, E. Kremer, F. Otto, O. Brenner, A. Lev-Tov, Y. Groner, The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J. 21, 3454–3463 (2002)CrossRefPubMed
40.
K. Inoue, S. Ozaki, T. Shiga, K. Ito, T. Masuda, N. Okado, T. Iseda, S. Kawaguchi, M. Ogawa, S.C. Bae, N. Yamashita, S. Itohara, N. Kudo, Y. Ito, Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat. Neurosci. 5, 946–954 (2002)CrossRefPubMed
41.
H.M. Robinson, Z.J. Broadfield, K.L. Cheung, L. Harewood, R.L. Harris, G.R. Jalali, M. Martineau, A.V. Moorman, K.E. Taylor, S. Richards, C. Mitchell, C.J. Harrison, Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 17, 2249–2250 (2003)CrossRefPubMed
42.
G.L. Barnes, K.E. Hebert, M. Kamal, A. Javed, T.A. Einhorn, J.B. Lian, G.S. Stein, L.C. Gerstenfeld, Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 64, 4506–4513 (2004)CrossRefPubMed
43.
A. Kilbey, K. Blyth, S. Wotton, A. Terry, A. Jenkins, M. Bell, L. Hanlon, E.R. Cameron, J.C. Neil, Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res. 67, 11263–11271 (2007)CrossRefPubMed
44.
V. Vladimirova, A. Waha, K. Luckerath, P. Pesheva, R. Probstmeier, Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J. Neurosci. Res. 86, 2450–2461 (2008)CrossRefPubMed
Metadata
Title
RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors
Authors
He-Yu Zhang
Long Jin
Gail A. Stilling
Katharina H. Ruebel
Kendra Coonse
Yoshinori Tanizaki
Avraham Raz
Ricardo V. Lloyd
Publication date
01-02-2009
Publisher
Springer US
Published in
Endocrine / Issue 1/2009
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-008-9129-z

Other articles of this Issue 1/2009

Endocrine 1/2009 Go to the issue

Original Paper

Estrogen stimulates the human endometrium to express a factor(s) that promotes vascular smooth muscle cell migration as an early step in microvessel remodeling

Original Paper

Protective effects of antioxidant-fortified diet on renal function and metabolic profile in obese Zucker rat

Original Paper

Gene and protein expression of p53 and p21 in fibroadenomas and adjacent normal mammary tissue

Original Paper

Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway

Original Paper

Interference at work: a case report of a malfunctioning insulin pump

Original Paper

Parathyroid hormone-related protein regulates osteoclast inhibitory lectin expression via multiple signaling pathways in osteoblast-like cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits